Penumbra stock pops after Boston Scientific’s $14.5 billion buyout — what PEN investors watch next
New York, Jan 15, 2026, 16:52 (EST) — After-hours Penumbra, Inc. shares jumped 11.8% to $350.49 in after-hours trading Thursday after Boston Scientific announced plans to acquire the clot-removal device maker in a roughly $14.5 billion deal. The stock reached an after-hours high of $369.84 but remained about $23 short of the $374 offer price, reflecting lingering merger risk and time before closing. (Reuters) The deal comes as major medical device companies seek expansion in vascular care, where demand is rising for less invasive stroke and blood clot treatments. Thrombectomy — removing clots from blood vessels — remains a critical